Related to Exact Receives $22.65M from Genzyme in Asset Purchase Agreement and Equity Investment

• Bayer Inks Commercialization Agreement with Genzyme Worth up to $2B
  
• Genzyme Acquires MS and CLL Therapy as well as Two More Oncology Products from Bayer
  
• Sequenom Reduces Workforce in Genetic Analysis Unit
  
• Genzyme Enlists Ergomed to Progress Anticancer Agent
  
• Genzyme to Evaluate to-BBB’s Technology for Delivering Biologics to the Brain
  
• Genzyme and Arecor Ally to Advance Protein Therapeutics
  
• Genzyme and Isis Complete Phase III Program for LDL-C Reducing Therapy
  
• PTC Therapeutics Receives $1.6M from FDA Orphan Drug Grant
  
• Genzyme Divests Diagnostics Business to Sekisui Chemical for $265M
  
• Roche Sublicenses EGFR IP from Genzyme to Develop Tarceva Companion Diagnostic
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Sequenom Purchases Illumina Sequencing Platform to Develop Trisomy 21 Test
  
• TrovaGene Regains Rights to Prenatal Applications of Transrenal MDx Technology from Sequenom
  
• Sequenom and LifeCodexx Ally to Bring Maternal Blood-Based Trisomy 21 Test to Europe
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study
  
• Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug
  
• Genzyme and Cystic Fibrosis Foundation Therapeutics Ink Research Deal
  
• Exact Sciences Closes $8.2M Placement and Inks Deal with Mayo Clinic
  
• Exact Sciences Fortifies Position in Stool-Based DNA Detection Through Deal with Hologic
  
• Exact Sciences Obtains OncoMethylome Biomarkers for Colorectal Cancer Test